急性扁桃炎に対する持続性Amoxicillin(C-AMOX)の臨床評価(Amoxicillin capsuleを対照とする二重盲検試験)

概要

論文の詳細を見る
A double-blind study was performed in order to evaluate the efficacy and safety of continuous acting preparation of Amoxicillin (C-AMOX) (1, 000mg/day b. i. d.) as compared with Amoxicillin capsule (AMPC) (1, 000mg/day q. i. d.) in acute tonsillitis, and the following results were obtained.1) The overall efficacy of C-AMOX and AMPC were 90.4% and 76.0%, respectively, and there was no statistically significant difference between the two drugs.2) Global improvement rating by doctors, however, was 98.1% for C-AMOX and 78.1% for AMPC. C-AMOX tended to be more effective than AMPC and the rate of usefulness of C-AMOX was also significantly higher than that of AMPC.3) The incidence of adverse reaction was 5.4% in 56 cases with C-AMOX and 9.3% in 54 cases with AMPC. No significant difference was observed between the two drugs.The results indicate that C-AMOX showed significantly higher efficacy and usefulness, and that C-AMOX was the same as or tended to be more effective than AMPC in the therapy of acute tonsillitis.
耳鼻咽喉科臨床学会の論文